ABSTRACT
Objective To study the curative effect and the safety of olmesartan medoxomil in patients with mild to moderate primary hypertension.Methods 121 patients with mild to moderate essential hypertension were randomized into two groups:olmesartan group (n =60),received olmesartan 20mg/day and valsartan group (n =61),received valsartan 8mg/day.Before and after the 8 weeks treatment,blood pressurem,ECG,blood and urinary laboratory exanination were observed in EH cases.Results After 8 weeks,Compared to valsartan group,the olmesartan group showed significantly erduction in both systolic blood pressure [(120.54 ± 12.78) mmrn Hg:(128.32 ± 10.01) mm Hg]and diastolic blood pressure[(73.27 ± 4.01) mm Hg:(79.65 ± 4.89) mm Hg].In terms of the 24 h ABPM,olmesartan monotherapy exhibited a sustained 24h BP reduction profile with the trough-to-peak ratios more than 50％.The side effect in olmesartan group was 2 cases,and 5 cases in valsartan group.Conclusion Candesartan cilexetil can be used in the treatment of patients with mild and moderate essential hypertension effectively and safely.
ABSTRACT
Hypertension is a serious health problem due to high frequency and concomitant other diseases including cardiovascular and renal dysfunction. Olmesartan cilexetil is a new antihypertensive drug associated with angiotensin II receptor antagonist. This study was conducted to evaluate the mutagenicity of olmesartan cilexetil by bacterial reverse mutation test using Salmonella typhimurium (TA100, TA1535, TA98, and TA1537) and Escherichia coli (WP2 uvrA). At the concentrations of 0, 62, 185, 556, 1667, and 5000 microg/plate, olmesartan cilexetil was negative in both Salmonella typhimurium and Escherichia coli regardless of presence or absence of metabolic activation system (S9 mix). These results demonstrate that olmesartan cilexetil does not induce bacterial reverse mutation.